Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Merck & Co., Inc. regarding a class action lawsuit related to misleading statements about the expected revenue from Gardasil sales, which has led to a significant decline in Merck's stock price [1]. Group 1: Allegations and Impact - The lawsuit alleges that Merck provided investors with material information indicating expected revenue of $11 billion from Gardasil sales by 2030, supported by optimistic forecasts about demand in China [1]. - On February 4, 2025, Merck announced it would not achieve the projected $11 billion in sales, citing a halt in shipments to China due to over-inflated inventories and lower-than-expected demand [1]. - Following this announcement, Merck's stock price dropped from $99.79 per share on February 3, 2025, to $90.74 per share on February 4, 2025, representing a decline of over 9% in one day [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of MRK during the specified class period are encouraged to register for the class action, with a deadline of April 14, 2025, to seek lead plaintiff status [2]. - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that artificially inflated stock prices [3].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Merck & Co., Inc. for alleged misrepresentations regarding the demand for its vaccine drug Gardasil in China, impacting investor confidence and inventory levels [1][2]. Group 1: Lawsuit Details - The lawsuit represents investors who purchased Merck securities between February 3, 2022, and February 3, 2025 [1]. - Allegations include that Merck lacked visibility into the demand for Gardasil in China, leading to inflated inventory levels at its distributor, Zhifei [2]. Group 2: Legal Process - Interested parties wishing to serve as lead plaintiff must file by April 14, 2025, with the role involving directing the litigation on behalf of the class [3]. - Shareholders can remain absent class members without taking action, and all representation is on a contingency fee basis, meaning no fees or expenses are required from shareholders [3]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" and listed in The Legal 500 for sixteen consecutive years [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Merck To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Merck between February 3, 2022 and February 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 19, 2025 (GLOBE N ...

Core Viewpoint - A class action lawsuit has been filed against Merck & Co., Inc. for alleged violations of securities laws, specifically related to misleading statements about the demand for its product Gardasil in China and inflated inventory issues [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Merck's securities between February 3, 2022, and February 3, 2025, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Merck - The complaint alleges that Merck made false and misleading statements regarding its consumer activation and education efforts for Gardasil, particularly in China [4]. - The company was overly optimistic about Gardasil's demand while concealing negative facts about actual demand and inflated inventory held by its distributor, Zhifei [4]. - As a result of these misleading statements, investors suffered damages when the truth about Merck's situation was revealed [4].

NEW YORK, Feb. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Merck investors who were adversely affected by alleged securities fraud between February 3, 2022 and February 3, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form? ...

NEW YORK, Feb. 16, 2025 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or "the Company") (NYSE: MRK) and certain of its officers.Class DefinitionThis lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Merck securities betwe ...

SAN DIEGO, Feb. 15, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Merck & Co., Inc. (NYSE: MRK) securities between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"), have until April 14, 2025 to seek appointment as lead plaintiff of the Merck class action lawsuit.  Captioned Cronin v. Merck & Co., Inc., No. 25-cv-01208 (D.N.J.), the Merck class action lawsuit charges Merck and certain of Merck's top executives with violations o ...

SAN DIEGO, Feb. 14, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Merck & Co., Inc. (NYSE: MRK) securities between February 3, 2022 and February 3, 2025. Merck is a global healthcare company.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Allegations that Merck & Co., Inc. (MRK) Misled Investors Regarding ...

NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2025.So what: If you purchased Merck securities during the Class Period you ma ...

Core Viewpoint - Buying dividend stocks at a cheap valuation can be advantageous, especially if the underlying business remains strong despite a price decline, allowing investors to benefit from higher yields and potential price rebounds [1]. Group 1: PepsiCo - PepsiCo's shares are currently at their lowest price since 2021, with a low price-to-earnings (P/E) ratio observed only a few times in the past five years [3]. - The company has faced slowing growth rates and consumer pushback against price hikes, leading to decreased investor enthusiasm [4]. - In Q4 2024, PepsiCo's revenue was $27.8 billion, nearly flat compared to Q4 2023, but profits increased by 16% to over $1.5 billion. The stock has declined approximately 14% over the past year, with a current dividend yield of 3.6% [5]. Group 2: United Parcel Service (UPS) - UPS shares dropped over 16% following earnings release and a strategic shift away from reliance on Amazon, which will reduce Amazon delivery volumes to less than half by the second half of 2026 [6]. - CEO Carol Tome indicated that this strategy may enhance overall profitability despite lower revenue, focusing on better margins rather than just sales growth [7]. - UPS projects $89 billion in revenue for the current year, down from $91.1 billion in 2024, but the stock offers a high yield of 4.9%, significantly above the S&P 500 average of 1.2% [8]. Group 3: Merck - Merck's current dividend yield is 3.3%, with shares trading at their lowest since late 2022 [9]. - The company has paused shipments of its Gardasil vaccine to China due to weak demand, raising concerns about future sales amid potential trade tensions [10]. - There are worries about significant sales declines for Merck's top-selling cancer drug, Keytruda, as biosimilars may enter the market as early as 2028 [11]. - Despite current challenges, Merck's stock is trading at less than 10 times estimated future earnings, making it a potentially attractive long-term investment [12]. - Investors are advised to remain patient with Merck, as it continues to work on new product developments [13].